Bender Robert & Associates Jounce Therapeutics, Inc. Transaction History

Bender Robert & Associates

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 20, 2023	BUY	$0.9 - $1.85 $9,000 - $18,500	10,000 New	10,000 $18,000
Q2 2022 Jul 19, 2022	BUY	$2.8 - $7.67 $28,000 - $76,700	10,000 New	10,000 $30,000
Q2 2021 Jul 16, 2021	SELL	$6.58 - $10.66 $65,800 - $106,600	-10,000 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$6.73 - $13.87 $67,300 - $138,700	10,000 New	10,000 $103,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Bender Robert & Associates, based on Form 13F filings with the SEC.

Stay updated on Bender Robert & Associates with notifications on news.